FrancophonIA/ELRC3.0 huggingface dataset:
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 4.5 mg rivastigmine.
Croatian: Svaka raspadljiva tableta za usta sadrži rivastigmin hidrogentartarat koji odgovara 4,5 mg rivastigmina.
English: Fall
Croatian: Padanje
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine.
Croatian: Svaka raspadljiva tableta za usta sadrži rivastigmin hidrogentartarat koji odgovara 3 mg rivastigmina.
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine.
Croatian: Svaka raspadljiva tableta za usta sadrži rivastigmin hidrogentartarat koji odgovara 6 mg rivastigmina.
English: 28 x 1 orodispersible tablet:EU/1/09/525/042 30 x 1 orodispersible tablet:EU/1/09/525/043 56 x 1 orodispersible tablet:EU/1/09/525/044 60 x 1 orodispersible tablet:EU/1/09/525/045 112 x 1 orodispersible tablet:EU/1/09/525/046
Croatian: 28 x 1 raspadljiva tableta za usta: EU/1/09/525/042 30 x 1 raspadljiva tableta za usta: EU/1/09/525/043 56 x 1 raspadljiva tableta za usta: EU/1/09/525/044 60 x 1 raspadljiva tableta za usta: EU/1/09/525/045 112 x 1 raspadljiva tableta za usta: EU/1/09/525/046
English: 14 x 1 orodispersible tablet:EU/1/09/525/026 28 x 1 orodispersible tablet:EU/1/09/525/027 30 x 1 orodispersible tablet:EU/1/09/525/028 56 x 1 orodispersible tablet:EU/1/09/525/029 60 x 1 orodispersible tablet:EU/1/09/525/030 112 x 1 orodispersible tablet:EU/1/09/525/031
Croatian: 14 x 1 raspadljive tablete za usta: EU/1/09/525/026 28 x 1 raspadljiva tableta za usta: EU/1/09/525/027 30 x 1 raspadljiva tableta za usta: EU/1/09/525/028 56 x 1 raspadljiva tableta za usta: EU/1/09/525/029 60 x 1 raspadljiva tableta za usta: EU/1/09/525/030 112 x 1 raspadljiva tableta za usta: EU/1/09/525/031
English: 28 x 1 orodispersible tablet:EU/1/09/525/037 30 x 1 orodispersible tablet:EU/1/09/525/038 56 x 1 orodispersible tablet:EU/1/09/525/039 60 x 1 orodispersible tablet:EU/1/09/525/040 112 x 1 orodispersible tablet:EU/1/09/525/041
Croatian: 28 x 1 raspadljiva tableta za usta: EU/1/09/525/037 30 x 1 raspadljiva tableta za usta: EU/1/09/525/038 56 x 1 raspadljiva tableta za usta: EU/1/09/525/039 60 x 1 raspadljiva tableta za usta: EU/1/09/525/040 112 x 1 raspadljiva tableta za usta: EU/1/09/525/041
English: 28 x 1 orodispersible tablet:EU/1/09/525/032 30 x 1 orodispersible tablet:EU/1/09/525/033 56 x 1 orodispersible tablet:EU/1/09/525/034 60 x 1 orodispersible tablet:EU/1/09/525/035 112 x 1 orodispersible tablet:EU/1/09/525/036
Croatian: 28 x 1 raspadljiva tableta za usta: EU/1/09/525/032 30 x 1 raspadljiva tableta za usta: EU/1/09/525/033 56 x 1 raspadljiva tableta za usta: EU/1/09/525/034 60 x 1 raspadljiva tableta za usta: EU/1/09/525/035 112 x 1 raspadljiva tableta za usta: EU/1/09/525/036
English: A mild eye/mucosal irritation potential of rivastigmine was identified in a rabbit study.
Croatian: Ispitivanje rivastigmina na zečevima ukazalo je na blagi potncijal iritacije oka/sluznice
English: Busuttil Ltd. Tel: +356 21 445 885
Croatian: Tel: +356 21 445 885
English: Elderly
Croatian: Distonija
English: Gait abnormality
Croatian: Fibrilacija atrija
English: • Stomach problems such as feeling sick (nausea) or being sick (vomiting), diarrhoea
Croatian: - Općenito loše osjećanje - Drhtanje ili osjećaj zbunjenosti - Smanjen apetit - Noćne more
English: Fatigue and asthenia Malaise
Croatian: Anksioznost Nemir
English: КРКА България ЕООД Teл.
Croatian: E.J. Busuttil Ltd.
English: It is used in the following groups:
Croatian: Primjenjuje se u sljedećim skupinama:
English: This means that Eptifibatide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Integrilin.
Croatian: To znači da je Eptifibatide Accord sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Integrilin.
English: This reduces the risk of a blood clot forming and helps prevent heart attacks.
Croatian: To smanjuje rizik od stvaranja krvnog ugruška i pomaže u sprečavanju srčanih udara.
English: The recommended dose is 180 micrograms per kilogram body weight given as an injection into a vein as soon as possible after diagnosis.
Croatian: Preporučena je doza 180 mikrograma po kilogramu tjelesne težine, koja se daje injekcijom u venu što prije nakon postavljanja dijagnoze.
English: The full EPAR and risk management plan summary for Eptifibatide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) i sažetak plana upravljanja rizikom za Eptifibatide Accord nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Eptifibatide Accord is given with aspirin and unfractionated heparin (other medicines that prevent blood clots).
Croatian: Eptifibatide Accord daje se zajedno s aspirinom i nefrakcioniranim heparinom (drugi lijekovi koji sprečavaju krvne ugruške).
English: The company provided data from the published literature on eptifibatide.
Croatian: Tvrtka je pružila podatke iz objavljene literature o eptifibatidu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Eptifibatide Accord has been shown to be comparable to Integrilin.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno da je Eptifibatide Accord usporediv s Integrilinom.
English: Patients who have moderately reduced kidney function should receive a lower dose during the infusion.
Croatian: Bolesnicima kojima je umjereno smanjena funkcija rada bubrega trebaju primati manju dozu tijekom infuzije.
English: Because Eptifibatide Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Eptifibatide Accord generički lijek, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: This is followed by a continuous infusion of 2.0 microgram/kg per minute which is continued for up to 72 hours, until the start of heart surgery, or until discharge from the hospital, whichever occurs first.
Croatian: Nakon toga se daje kontinuirana infuzija od 2,0 mikrograma/kg u minuti, što se nastavlja do najviše 72 sata, sve do početka operacije srca ili otpuštanja iz bolnice (ovisno o tome što se prvo dogodi).
English: The patients most likely to benefit from a treatment with Eptifibatide Accord are those at high risk of heart attack in the three to four days after the start of acute (sudden) angina.
Croatian: Bolesnici za koje postoji najveća vjerojatnost da će imati koristi od liječenja lijekom Eptifibatide Accord jesu bolesnici s visokim rizikom od srčanog udara tri do četiri dana nakon početka akutne (iznenadne) angine.
English: This includes patients who are having percutaneous transluminal coronary angiography (PTCA, a type of surgery to clear the arteries supplying the heart).
Croatian: To uključuje bolesnike koji imaju perkutanu transluminalnu koronarnu angiografiju (PTCA, vrsta operacije kojom se čiste arterije koje opskrbljuju srce).
English: If the patient undergoes a percutaneous coronary intervention (PCI or angioplasty, a surgical procedure that is used to unblock narrowed coronary arteries), infusion of Eptifibatide Accord can be continued for up to 24 hours after the procedure, with a maximum treatment duration of 96 hours.
Croatian: Ako je bolesnik podvrgnut perkutanoj koronarnoj intervenciji (PCI ili angioplastika ili kirurški zahvat koji se primjenjuje kako bi se odblokirale sužene koronarne arterije), infuzija lijeka Eptifibatide Accord može se nastaviti do najviše 24 sata nakon zahvata, pri čemu liječenje može trajati najdulje 96 sati.
English: Eptifibatide Accord is a ‘generic medicine'.
Croatian: Eptifibatide Accord je „generički lijek”.
English: Eptifibatide Accord is a medicine used to prevent a heart attack in adults.
Croatian: Eptifibatide Accord je lijek koji se koristi za sprečavanje srčanog udara u odraslih.
English: This sticking together of platelets is an important step in forming a blood clot, and when it happens in the blood vessels supplying the heart it can lead to a heart attack.
Croatian: Sljepljivanje trombocita važan je element stvaranja krvnog ugruška i, ako se dogodi u krvnim žilama koje opskrbljuju srce, može dovesti do srčanog udara.
English: • patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
Croatian: • u bolesnika koji su već imali infarkt miokarda bez formiranog Q zupca (vrsta srčanog udara), s bolovima u prsima u posljednja 24 sata i s abnormalnostima na elektrokardiogramu (EKG-u) ili znakovima srčanih problema u krvi.
English: The active substance in Eptifibatide Accord, eptifibatide, stops the platelets aggregating by blocking a protein called glycoprotein IIb/III on their surface that helps make them sticky.
Croatian: Djelatna tvar u lijeku Eptifibatide Accord, eptifibatid, zaustavlja sljepljivanje trombocita blokiranjem proteina glikoprotein IIb/III na njihovoj površini, koji pomaže u njihovu sljepljivanju.
English: No additional studies were needed as Eptifibatide Accord is a generic medicine that is given by injection and infusion into a vein and contains the same active substance as the reference medicine, Integrilin.
Croatian: Nisu bila potrebna dodatna ispitivanja jer je Eptifibatide Accord generički lijek koji se daje injekcijom i infuzijom u venu i koji sadrži istu djelatnu tvar kao i referentni lijek Integrilin.
English: Eptifibatide Accord eptifibatide
Croatian: Eptifibatide Accord eptifibatid
English: The Committee recommended that Eptifibatide Accord be approved for use in the EU.
Croatian: Odbor je preporučio izdavanje odobrenja za primjenu lijeka Eptifibatide Accord u EU-u.
English: It is not intended to provide practical advice on how to use Eptifibatide Accord.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Eptifibatide Accord.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eptifibatide Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana u sažetak opisa svojstava lijeka i uputu o lijeku za Eptifibatide Accord uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: What measures are being taken to ensure the safe and effective use of Eptifibatide Accord?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Eptifibatide Accord?
English: A risk management plan has been developed to ensure that Eptifibatide Accord is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Eptifibatide Accord.
English: It is available as solutions for infusion (drip) and injection into a vein.
Croatian: Dostupan je u obliku otopine za infuziju (drip) koja se daje u venu.
English: This is a summary of the European public assessment report (EPAR) for Eptifibatide Accord.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Eptifibatide Accord.
English: Eptifibatide Accord should be given by a doctor who has experience in the management of heart attacks and angina and can only be obtained with a prescription.
Croatian: Eptifibatide Accord propisuje liječnik s iskustvom u liječenju srčanih udara i angine te se izdaje samo na liječnički recept.
English: Other information about Eptifibatide Accord
Croatian: Ostale informacije o lijeku Eptifibatide Accord
English: • patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger);
Croatian: • u bolesnika koji imaju nestabilnu anginu (bol u prsima uzrokovana slabim protokom krvi do srca, koja se može javiti pri mirovanju ili bez nekog očitog uzroka);
English: The medicine contains the active substance eptifibatide.
Croatian: Lijek sadrži djelatnu tvar eptifibatid.
English: What is Eptifibatide Accord and what is it used for?
Croatian: Što je Eptifibatide Accord i za što se koristi?
English: For more information about treatment with Eptifibatide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Eptifibatide Accord pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: Eptifibatide Accord must not be used in patients with severe kidney problems.
Croatian: Eptifibatide Accord ne smije se primjenjivati u bolesnika s ozbiljnim problemima u funkciji rada bubrega.
English: Eptifibatide Accord is an inhibitor of platelet aggregation.
Croatian: Eptifibatide Accord je inhibitor agregacije trombocita.
English: This means that it helps to prevent cells in the blood called platelets sticking together (aggregating).
Croatian: To znači da pomaže u sprečavanju sljepljivanja (agregacije) stanica u krvi koje se nazivaju trombociti.
English: What are the benefits and risks of Eptifibatide Accord?
Croatian: Koje su koristi i rizici lijeka Eptifibatide Accord?
English: For practical information about using Eptifibatide Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Eptifibatide Accord pročitajte u uputi o lijeku, odnosno obratite se svojem liječniku ili ljekarniku.
English: Therefore, the CHMP's view was that, as for Integrilin, the benefit outweighs the identified risk.
Croatian: Stoga je stajalište Odbora da koristi nadmašuju utvrđene rizike, kao i kod Integrilina.
English: Why is Eptifibatide Accord approved?
Croatian: Zašto je Eptifibatide Accord odobren?
English: How does Eptifibatide Accord work?
Croatian: Kako djeluje Eptifibatide Accord?
English: How is Eptifibatide Accord used?
Croatian: Kako se Eptifibatide Accord koristi?
English: How has Eptifibatide Accord been studied?
Croatian: Kako je Eptifibatide Accord ispitivan?
English: Skilarence is available as tablets (30 and 120 mg).
Croatian: Skilarence je dostupan u obliku tableta (30 i 120 mg).
English: Tablets should be swallowed whole during or immediately after a meal.
Croatian: Tablete se moraju progutati cijele tijekom ili neposredno nakon obroka.
English: The full EPAR for Skilarence can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Skilarence nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The main measure of effectiveness was the proportion of patients who achieved a 75% reduction in their score for disease severity.
Croatian: Glavna mjera djelotvornosti bio je udio bolesnika u kojih je postignuto smanjenje od 75 % u pogledu težine bolesti.
English: Psoriasis results from over-activity of the body's immune (defence) system.
Croatian: Psorijaza je posljedica prekomjerne aktivnosti imunosnog (obrambenog) sustava.
English: Skilarence dimethyl fumarate
Croatian: Skilarence dimetilfumarat
English: Other information about Skilarence
Croatian: Ostale informacije o lijeku Skilarence
English: What measures are being taken to ensure the safe and effective use of Skilarence?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Skilarence?
English: The company that markets Skilarence will supply educational materials to healthcare professionals about the risk of serious infections, including PML, and how to minimise this risk.
Croatian: Tvrtka koja stavlja na tržište lijek Skilarence osigurat će zdravstvenim radnicima obrazovne materijale o riziku od ozbiljnih infekcija, uključujući PML, te o tome kako minimizirati taj rizik.
English: The starting dose is 30 mg once a day and the dose is increased every week according to the schedule shown in the package leaflet until the psoriasis starts improving or until the patient is taking the maximum dose of 240 mg three times a day.
Croatian: Početna doza od 30 mg jedanput dnevno povećava se svaki tjedan u skladu s rasporedom navedenim u uputi o lijeku sve dok se stanje prouzročeno psorijazom ne poboljša ili dok bolesnik ne dostigne maksimalnu dozu od 240 mg triput dnevno.
English: What is Skilarence and what is it used for?
Croatian: Što je Skilarence i za što se koristi?
English: It is not intended to provide practical advice on how to use Skilarence.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Skilarence.
English: After 16 weeks of treatment, 37% of patients taking Skilarence achieved this reduction, compared with 15% taking placebo and 40% taking Fumaderm .
Croatian: Nakon 16 tjedana liječenja, takvo je smanjenje postignuto u 37 % bolesnika koji su uzimali Skilarence, u odnosu na 15 % bolesnika koji su uzimali placebo i 40 % bolesnika koji su uzimali Fumaderm.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Skilarence have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Skilarence nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Skilarence is a medicine used to treat plaque psoriasis, a disease that causes thickened, red and inflamed areas of skin with scaly patches.
Croatian: Skilarence je lijek koji se upotrebljava za liječenje plak psorijaze, bolesti koja uzrokuje zadebljana, crvena i upaljena područja na koži pokrivena ljuskama.
English: Because Skilarence reduces the activity of the immune system, there is a risk of serious infections, including progressive multifocal leukoencephalopathy (PML, a brain infection), but the risk can be minimised by regular tests for white blood cell counts and stopping treatment if necessary.
Croatian: Budući da lijek Skilarence smanjuje aktivnost imunosnog sustava, postoji rizik od ozbiljnih infekcija i progresivne multifokalne leukoencefalopatije (PML, infekcija mozga), ali taj se rizik može minimizirati redovitim mjerenjem broja bijelih krvnih stanica i prekidom liječenja ako je to potrebno.
English: What are the risks associated with Skilarence?
Croatian: Koji su rizici povezani s lijekom Skilarence?
English: Skilarence must not be used in patients who have severe problems of the digestive system, liver or kidneys.
Croatian: Skilarence ne smiju uzimati bolesnici koji imaju teške probleme s probavnim sustavom, jetrom ili bubrezima.
English: The active substance in Skilarence, dimethyl fumarate, reduces the activity of the immune system.
Croatian: Djelatna tvar lijeka Skilarence, dimetilfumarat, smanjuje aktivnost imunosnog sustava.
English: The CHMP considered that the main study has shown Skilarence's short-term effectiveness, and published studies with similar medicines show that the effectiveness is maintained with continued use.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) smatra da se u glavnom ispitivanju dokazala kratkoročna djelotvornost lijeka Skilarence, a u objavljenim ispitivanjima sličnih lijekova pokazalo se da se djelotvornost zadržava stalnom uporabom.
English: This is a summary of the European public assessment report (EPAR) for Skilarence.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Skilarence.
English: A main study involving 704 patients with moderate to severe plaque psoriasis found that Skilarence was more effective than placebo (dummy treatment) at treating the disease and as effective as Fumaderm (a psoriasis medicine that contains dimethyl fumarate and monoethyl fumarate).
Croatian: U glavnom ispitivanju koje je obuhvatilo 704 bolesnika s umjerenom do teškom plak psorijazom Skilarence se pokazao djelotvornijim u liječenju bolesti od placeba (prividno liječenje) i jednako djelotvornim kao Fumaderm (lijek za psorijazu koji sadržava dimetilfumarat i monoetilfumarat).
English: It is used in patients with moderate or severe disease for whom treatments applied direct to the skin do not work well enough.
Croatian: Upotrebljava se u bolesnika s umjerenom ili teškom bolešću koji nisu dovoljno dobro reagirali na lijekove koji se primjenjuju izravno na kožu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Skilarence's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi lijeka Skilarence nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: It must also not be used by women during pregnancy or if breast-feeding.
Croatian: Osim toga, ne smiju ga uzimati žene koje su trudne ili koje doje.
English: Skilarence can only be obtained with a prescription and it should be used under the supervision of a doctor who has experience in diagnosing and treating psoriasis.
Croatian: Skilarence se izdaje samo na recept i namijenjen je za primjenu pod nadzorom liječnika iskusnog u dijagnosticiranju i liječenju psorijaze.
English: The most common side effects with Skilarence (which may affect more than 1 in 10 people) are effects on the digestive system (diarrhoea, bloating, belly ache and nausea), flushing (reddening of the skin) and low levels of lymphocytes (type of white blood cells) or of white blood cells in general.
Croatian: Najčešće nuspojave lijeka Skilarence (koje se mogu javiti u više od 1 na 10 osoba) jesu učinci na probavni sustav (proljev, napuhnutost, bol u želucu i mučnina), navale crvenila (crvenilo kože) i smanjen broj limfocita (vrsta bijelih krvnih stanica) ili bijelih krvnih stanica općenito.
English: It is thought to act on T cells (a type of white blood cell that forms part of the immune system) to prevent the cells from producing substances that cause inflammation and lead to psoriasis.
Croatian: Smatra se da lijek djeluje na Tstanice (vrsta bijelih krvnih stanica koje čine imunosni sustav) i sprečava da stanice stvaraju tvari koje uzrokuju upalu i dovode do psorijaze.
English: Why is Skilarence approved?
Croatian: Zašto je lijek Skilarence odobren?
English: The doctor may reduce the dose when the psoriasis has been brought under control.
Croatian: Liječnik može smanjiti dozu kad se postigne dobra kontrola stanja prouzročenog psorijazom.
English: How does Skilarence work?
Croatian: Kako djeluje Skilarence?
English: Skilarence contains the active substance dimethyl fumarate.
Croatian: Skilarence sadržava djelatnu tvar dimetilfumarat.
English: For more information about treatment with Skilarence, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Skilarence pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svom liječniku ili ljekarniku.
English: What benefits of Skilarence have been shown in studies?
Croatian: Koje su koristi lijeka Skilarence dokazane u ispitivanjima?
English: For practical information about using Skilarence, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Skilarence bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: Most side effects are mild or moderate.
Croatian: Većina nuspojava bila je blaga do umjerena.
English: How is Skilarence used?
Croatian: Kako se Skilarence koristi?
English: For the full list of all side effects reported with Skilarence, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Skilarence potražite u uputi o lijeku.